{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:09:01Z","timestamp":1740107341434,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00415-024-12542-7","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T16:05:46Z","timestamp":1720022746000},"page":"6363-6367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report"],"prefix":"10.1007","volume":"271","author":[{"given":"Uro\u0161","family":"Rot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miha","family":"Jerala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alenka","family":"Horvat Ledinek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-5974","authenticated-orcid":false,"given":"Gregor","family":"Brecl Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"12542_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-023-01383-4","volume":"47","author":"LV Rindi","year":"2024","unstructured":"Rindi LV, Zace D, Braccialarghe N, Massa B, Barchi V, Iannazzo R, Fato I, De Maria F, Kontogiannis D, Malagnino V, Sarmati L, Iannetta M (2024) Drug-induced progressive multifocal leukoencephalopathy (PML): a systematic review and meta-analysis. Drug Saf 47:333\u2013354","journal-title":"Drug Saf"},{"key":"12542_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstrom E, Dahlke F, Investigators EC (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:1263\u20131273","journal-title":"Lancet"},{"key":"12542_CR3","unstructured":"Novartis 2024: siponimod: global website with up-to-date safety information for healthcare professionals. www.siponimodinfo.com\/en\/key-safety-topics\/pml. Accessed 25 May 2024"},{"key":"12542_CR4","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1007\/s00415-021-10910-1","volume":"269","author":"S Sriwastava","year":"2022","unstructured":"Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, Khalid SH, Lisak RP (2022) Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol 269:1678\u20131687","journal-title":"J Neurol"},{"key":"12542_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","volume":"78","author":"A Patel","year":"2021","unstructured":"Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, Purohit D, Haroutunian V, Williamson A, Koralnik I, Harel A (2021) Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol 78:736\u2013740","journal-title":"JAMA Neurol"},{"key":"12542_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458520949158","volume":"28","author":"AL Jordan","year":"2022","unstructured":"Jordan AL, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y (2022) Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler 28:7\u201315","journal-title":"Mult Scler"},{"key":"12542_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.msard.2014.09.215","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G (2015) A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. Mult Scler Relat Disord 4:83\u201384","journal-title":"Mult Scler Relat Disord"},{"key":"12542_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-3-031-33013-1_23","volume-title":"Mind, brain and education","author":"U Rot","year":"2023","unstructured":"Rot U, Emer\u0161i\u010d A (2023) Contemporary cerebrospinal fluid analysis in multiple sclerosis. In: Demarin V, Battistin L, Budin\u010devi\u0107 H (eds) Mind, brain and education. Springer, Dordrecht, pp 243\u2013252"},{"key":"12542_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1212\/WNL.0000000000207622","volume":"101","author":"F Schweitzer","year":"2023","unstructured":"Schweitzer F, Laurent S, Cortese I, Fink GR, Silling S, Skripuletz T, Metz I, Wattjes MP, Warnke C (2023) Progressive multifocal leukoencephalopathy: pathogenesis, diagnostic tools, and potential biomarkers of response to therapy. Neurology 101:700\u2013713","journal-title":"Neurology"},{"key":"12542_CR10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","volume":"77","author":"J Kuhle","year":"2011","unstructured":"Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O, Radue EW, Ryschkewitsch C, Major EO, Kappos L, Frank S, Hirsch HH (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77:2010\u20132016","journal-title":"Neurology"},{"key":"12542_CR11","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1111\/ene.15021","volume":"28","author":"N Lambert","year":"2021","unstructured":"Lambert N, El Moussaoui M, Maquet P (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: identifying relevant outcome factors. Eur J Neurol 28:3814\u20133819","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12542-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:18:15Z","timestamp":1725538695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12542-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12542"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12542-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Uro\u0161 Rot has received consultation fees\/Honoraria from Bayer, Biogen, Lek, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and Grants\/Research support from Biogen and Novartis. Alenka Horvat Ledinek Participated as a clinical investigator and\/or received consultation and\/or speaker fees from: Biogen, Lek, Merck, Novartis, Pliva\/Teva, Roche, Sanofi Genzyme. Miha Jerala reports no conflicts of interest. Gregor Brecl Jakob Participated as a clinical investigator and\/or received consultation and\/or speaker fees from: Amgen, AstraZeneca, Biogen, Lek, Merck, Novartis, Pliva\/Teva, Roche, Sanofi Genzyme, Swixx, Viatris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The patient gave informed consent to anonymously report his case. Our institution does not require ethical approval for reporting individual cases or case series.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}